Canadian Journal of Infectious Diseases and Medical Microbiology / 2018 / Article / Tab 3

Review Article

Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli

Table 3

Fosfomycin (FOS) treatment for acute and chronic bacterial prostatitis caused by antimicrobial-resistant E. coli.

ReferenceSubject numberType of bacterial prostatitisaAgeSusceptibilityFOS MICMDRd mechanismFT e dosage regimenFT treatment durationMicrobiological eradicationClinical cure
CIPbTMP-SMXc

[7]1C80RgRAmpC3 g·q 72 h6 weeksYesYes
2C52RRESBLi3 g·q 72 h6 weeksYesYes
3C54RSESBL3 g·q 72 h6 weeksNoNo
4C54RR3 g·q 72 h6 weeksNoNo
5C31RS3 g·q 72 h6 weeksNoNo
6C29ShSESBL3 g·q 72 h6 weeksYesYes
7C57RR3 g·q 72 h6 weeksYesYes
8C22RR3 g·q 72 h6 weeksYesYes
9C44SR3 g·q 72 h6 weeksNoNo
10C59RSESBL3 g·q 72 h6 weeksYesYes
11C49RR3 g·q 72 h6 weeksYesNo
12C70RS3 g·q 72 h6 weeksNoNo
13C65SS3 g·q 48 h6 weeksNoNo
14C54SS3 g·q 48 h6 weeksYesYes
[24]1A/C73R1 μg/mLESBL3 g OD/BID16 weeksYesYes
2A80R1 μg/mLESBL3 g OD12 weeksYesYes
[22]1C53R2 μg/mLESBL3 g·q 72 h2 weeksYesYes
[25]13 totalC53.6f8/13 R7/13 R13/13 S2/13 ESBL3 g OD q 48 h7 weeks∼77%

aA, acute prostatitis; C, chronic prostatitis; U, unspecified; bCIP, ciprofloxacin; cTMP-SMX, trimethoprim-sulfamethoxazole; dMDR, multidrug-resistant; eFT, fosfomycin tromethamine; fmean age (years); gR, resistant; hS, susceptible; iESBL, extended-spectrum β-lactamase; jMBL, metallo-β-lactamase; combination therapy of oral FT (3 g q 72 h) and oral doxycycline (100 mg q 12 h).

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.